Akebia Therapeutics (AX9) Stock Statistics & Valuation Metrics

Akebia Therapeutics has a market cap or net worth of CHF286.40M. The enterprise value is CHF424.77.

Akebia Therapeutics has ― shares outstanding. The number of shares has decreased by -2.65% in one year.

Akebia Therapeutics’s return on equity (ROE) is -0.16 and return on invested capital (ROIC) is 9.26%.

The current PE Ratio of Akebia Therapeutics is ―. Akebia Therapeutics’s PEG ratio is 0.83.

In the last 12 months, Akebia Therapeutics had revenue of 236.20M and earned -5.34M in profits. Earnings per share was -0.02.

In the last 12 months, operating cash flow was 60.37M and capital expenditures -427.00K, giving a free cash flow of 60.01M billion.

Akebia Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Akebia Therapeutics upcoming earnings date is Oct 29, 2026, After Close (Confirmed).

Akebia Therapeutics as a current ratio of 1.13, with Debt / Equity ratio of 45.64%

In the past 12 months, Akebia Therapeutics has paid 1.62M in taxes.

Akebia Therapeutics EV to EBITDA ratio is 20.50, with an EV/FCF ratio of 6.55.

Akebia Therapeutics has CHF162.64M in cash and marketable securities with CHF12.49M in debt, giving a net cash position of CHF150.15M billion.

Gross margin is 80.87%, with operating margin of 9.95%, and net profit margin of -2.26%.

The average price target for Akebia Therapeutics is CHF4.86, which is 11.43% higher than the current price. The consensus rating is Moderate Buy